RAIN Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Jan 2024 @ 16:00):

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States...

Stats
Today's Volume	3.70M
Average Volume	238 293
Market Cap	44.01M
EPS	$0 ( 2024-03-14 )
Next earnings date	( $0 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.585
ATR14	$0.0380 (3.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-26	Tang Kevin C	Sell	3 850 513	Common Stock
2024-01-25	Bvf Partners L P/il	Sell	185 388	Common Stock, $0.001 par value
2024-01-25	Bvf Partners L P/il	Sell	341 547	Non-Voting Common Stock, $0.001 par value
2024-01-26	Bvf Partners L P/il	Sell	35 000	Stock Option (Right to Buy)
2024-01-26	Bvf Partners L P/il	Sell	20 000	Stock Option (Right to Buy)

INSIDER POWER
-56.66
Last 98 transactions
Buy: 6 387 020 \| Sell: 11 238 556

Volume Correlation

Long: 0.27 (neutral)

Short: -0.45 (neutral)

Signal:(53.89) Neutral

Rain Therapeutics Inc. Correlation

10 Most Positive Correlations
ATRO	0.888
ORIC	0.886
PFMT	0.881
MDWD	0.878
VRNA	0.874
PRQR	0.874
IMVT	0.873
FTFT	0.869
IPHA	0.868
PMTS	0.865

10 Most Negative Correlations
SGLB	-0.843
SFET	-0.839
OP	-0.835
AMGN	-0.832
PEV	-0.827
RTPY	-0.822
SMIT	-0.82
GHVI	-0.819
MEDS	-0.818
MTEX	-0.818

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rain Therapeutics Inc. Correlation - Currency/Commodity

0.69
( moderate )

0.72
( moderate )

0.00
( neutral )

-0.64
( weak negative )

-0.67
( moderate negative )

-0.53
( weak negative )

Rain Therapeutics Inc. Financials

Annual	2022
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-2.71

Q3	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.190

Q2	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.610

Q1	2023
Revenue:	$0
Gross Profit:	$0 (0.00 %)
EPS:	$-0.530

Financial Reports:

No articles found.

Rain Therapeutics Inc.

Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.